Clinical Trial Update: Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing the safety and efficacy of YPEG-rhG-CSF in non-myeloid malignancies receiving chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-myeloid Malignancy

Drugs mentioned

• YPEG-rhG-CSF (pegylated recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Conditions: Non-Myeloid Malignancy | Phase 3 | Status: COMPLETED